Beijing Lideman Bio-Pharmaceutical Co., Ltd. announces changes in valuation institutions for its major asset restructuring. The valuation of the target asset, 100% equity of Beijing Sci-Ran Pharmaceutical Biological Products Co., Ltd., has been adjusted. The final transaction price for 61.50% equity is RMB 1,392.975 million, a decrease from the initial estimate.
Summary generated by AI · Always verify with source document
Securities Code: 300289 Stock Abbreviation: Lideman Announcement No.: 2026-040
Beijing Lideman Bio-Pharmaceutical Co., Ltd.
Announcement on Explanation of Differences in Valuation Before and After Changing Valuation Institutions for Major Asset Restructuring Project
The Company and the entire Board of Directors guarantee that the content of information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.